These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22338914)

  • 1. [Drug-induced hepatic injury, the challenge for cause investigation].
    Matsumoto K
    Rinsho Byori; 2011 Dec; 59(12):1117-22. PubMed ID: 22338914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.
    Iwanaga T; Kobayashi D; Hirayama M; Maeda T; Tamai I
    Drug Metab Dispos; 2005 Dec; 33(12):1791-5. PubMed ID: 16135657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity.
    Wang H; Peng Y; Zhang T; Lan Q; Zhao H; Wang W; Zhao Y; Wang X; Pang J; Wang S; Zheng J
    Drug Metab Dispos; 2017 Dec; 45(12):1354-1363. PubMed ID: 29021351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.
    Hautekeete ML; Henrion J; Naegels S; DeNeve A; Adler M; Deprez C; Devis G; Klöppel G
    Liver; 1995 Feb; 15(1):25-9. PubMed ID: 7776854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug-induced hepatitis due to benzarone (Fragivix): apropos of a clinical case report].
    Sepulchre D; De Plaen JL; Geubel AP
    Acta Gastroenterol Belg; 1990; 53(5-6):499-503. PubMed ID: 2130580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatitis caused by benzarone: a second case].
    Nakad A; Azzouzi K; Gerbaux A; Delcourt A; Sempoux C; Tamo F; Rahier J; Geubel AP
    Gastroenterol Clin Biol; 1990; 14(10):782-4. PubMed ID: 2262129
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of fulminant hepatitis, possibly caused by benzbromarone].
    Suzuki T; Suzuki T; Kimura M; Shinoda M; Fujita T; Miyake N; Yamamoto S; Tashiro K
    Nihon Shokakibyo Gakkai Zasshi; 2001 Apr; 98(4):421-5. PubMed ID: 11400273
    [No Abstract]   [Full Text] [Related]  

  • 9. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
    Nozawa T; Sugiura S; Nakajima M; Goto A; Yokoi T; Nezu J; Tsuji A; Tamai I
    Drug Metab Dispos; 2004 Mar; 32(3):291-4. PubMed ID: 14977862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity.
    Kaufmann P; Török M; Hänni A; Roberts P; Gasser R; Krähenbühl S
    Hepatology; 2005 Apr; 41(4):925-35. PubMed ID: 15799034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization patterns of antihyperuricemic agents following safety announcement on allopurinol and benzbromarone by Taiwan Food and Drug Administration.
    Cheng CL; Chao PH; Hsu JC; Weng MM; On AW; Yang YH
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):309-13. PubMed ID: 24307655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatic adverse effects of allopurinol].
    Lindh J
    Lakartidningen; 2009 Sep 16-22; 106(38):2374-5. PubMed ID: 19848345
    [No Abstract]   [Full Text] [Related]  

  • 14. Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways.
    Shih PH; Hwang SL; Yeh CT; Yen GC
    J Agric Food Chem; 2012 Mar; 60(11):2924-33. PubMed ID: 22364184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure.
    Felser A; Lindinger PW; Schnell D; Kratschmar DV; Odermatt A; Mies S; Jenö P; Krähenbühl S
    Toxicology; 2014 Oct; 324():136-46. PubMed ID: 25108121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.
    Imai S; Nasuhara Y; Momo K; Oki H; Kashiwagi H; Sato Y; Miyai T; Sugawara M; Takekuma Y
    Biol Pharm Bull; 2021; 44(10):1499-1505. PubMed ID: 34602558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfulminant hepatitis requiring liver transplantation after benzarone administration.
    Gehenot M; Horsmans Y; Rahier J; Geubel AP
    J Hepatol; 1994 Jun; 20(6):842. PubMed ID: 7930488
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.
    McDonald MG; Rettie AE
    Chem Res Toxicol; 2007 Dec; 20(12):1833-42. PubMed ID: 18020424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
    Yu TF
    J Rheumatol; 1976 Sep; 3(3):305-12. PubMed ID: 978666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.